deCODE Receives California Clinical Laboratory License
News Feb 24, 2009
deCODE genetics has announced that it has received a clinical laboratory license from the State of California. The quality and scale of deCODE’s in-house, CLIA-registered genotyping laboratory underpins deCODE’s global leadership in the discovery of variations in the sequence of the human genome conferring risk of common diseases.
The same staff and facility also process deCODE’s DNA-based reference laboratory tests for gauging individual risk of major public health challenges ranging from heart attack to breast cancer, as well as the company’s deCODEme™ scans. The company says that with this license, California residents can now benefit from the unrivalled quality of deCODE products for understanding risk and, working with their physicians, empowering the prevention of common diseases.
Through its reference laboratory testing service, www.decodediagnostics.com, deCODE offers DNA-based tests for assessing individual risk of heart attack, type 2 diabetes, stroke, breast cancer, prostate cancer, and glaucoma.
deCODEme™ is said to be the world’s first retail genome analysis service, available at www.decodeme.com. The full genome Complete Scan scan and the Cardio and Cancer scans build on deCODE’s discovery of common variations in the sequence of the human genome conferring increased risk of common diseases.
Ancient Fish Genes May Hold Key to Spinal Cord RepairNews
A study has found that genes controlling spinal cord repair in the lamprey fish are also active in mammals, which could provide a blueprint for treatment.READ MORE
Prostate Tumor Progression Dictated by Cancer’s Gene-determined “Immune Landscape”News
The field of immunotherapy is revolutionizing cancer treatment today. However, clinical trials often show marked improvements in only small subsets of patients, suggesting that as-yet unidentified variations among tumors result in distinct paths of disease progression and response to therapy.READ MORE